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ABSTRACT (max 200 words) 
OBJECTIVES 
To assess the validity of the Edinburgh Cognitive and Behaviour ALS Screen (ECAS), a multi-domain 
screen designed to detect cognitive deficits in patients with motor disorders.  
METHODS 
40 ALS patients (without pre-diagnosed dementia) and 40, age, gender and education matched 
healthy controls were recruited.  All participants underwent extensive neuropsychological 
assessment and the ECAS. Performance at neuropsychological assessment across five domains 
(fluency, executive function, language, memory and visuospatial function) was compared to the 
ECAS ALS-Specific (fluency; executive functions and social cognition; language), ALS Non-specific 
(memory; visuospatial functions), and total scores. 
RESULTS 
Data from the healthy controls produced population-based abnormality cut-offs: composite score 
performance < 2 SD in any domain classified impairment at neuropsychological assessment. 33% of 
patients were impaired, most commonly in a single domain (executive or language dysfunction). 
Receiver Operator Curve (ROC) analyses using ECAS total scores and ALS-Specific scores revealed 
85% sensitivity and 85% specificity in the detection of cognitive impairment characteristic of ALS 
(fluency, executive function, language). A five point borderline range produced optimal values (ALS-
Specific Score 77-82 and ECAS-Total Score 105-110)  
CONCLUSIONS 
Validation against gold standard extensive neuropsychology demonstrated that the ECAS is a 
screening tool with high sensitivity and specificity to impairment characteristic of ALS. 
 















Cognitive and behavioural changes in ALS are well recognized as integral to the disease. Recent 
research has demonstrated that such changes are heterogeneous with impairments not only in 
letter fluency and executive functions, but also in language and social cognition (see (1) for review). 
However extensive neuropsychology testing may not be appropriate for all patients due to 
increasing physical disability or not feasible due to limited time and resources. The challenge for 
neuropsychology has been to develop an appropriate screening test, which is quick and easy to 
perform and can be undertaken by health care professionals within the clinic or at home. Effective 
screening should identify who has cognitive impairment, what type of impairment is present, and 
how severe that impairment is (2). The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) (3) 
was launched as a rapid screening test to provide the early identification of these cognitive and 
behavioural changes in ALS. The screen has been validated against other generic screening measures 
(4). Here the test is validated against gold standard extensive neuropsychology.  
  




MATERIALS AND METHODS 
Participants 
Healthy Volunteers: Forty (26 male) healthy volunteers were recruited from spouses or friends of 
ALS patients, and through local voluntary organisations. The age and education levels of healthy 
volunteers were selected to closely match the patient comparison group. All participants were 
native English speakers, and scored above the cut-off for abnormality (82/100) in the Addenbrooke’s 
Cognitive Examination III (5) (mean 93.90, SD 4.44; range 85-100). No participant had a documented 
neurological or psychiatric history. 
 
ALS Patients: Recruitment took place through local ALS clinics and through the Scottish MND 
Register, a population based database of patients with MND living in Scotland.  40 (26 male) patients 
with ALS (38 sporadic, 2 familial – patients with a history of ALS in a first degree relative) were 
assessed. All patients had clinical and electrophysiological evidence of combined upper and lower 
motor neurone involvement and fulfilled the revised El Escorial criteria for clinically definite or 
probable ALS (6).  Six patients had bulbar onset of symptoms. Exclusion criteria included terminal 
stages of disease or major comorbid medical, neurological or psychiatric history including severe 
diabetes, epilepsy, alcohol/substance-related disorders, severe head injury or traumatic brain injury 
cerebrovascular disease or stroke. Disability was assessed using the ALS Functional Rating Scale-
Revised (ALSFRS-R; 7); mean ALS-FRS was 35.68 (range 11-47), and median duration of illness was 
25.5 months (range 5-221). Twenty three of 34 ALS patients had a Sniff Nasal Inspiratory Pressure 
(SNIP) score of lower than 40cmH(2)O (mean 32.5, SD 15.24, range 10-74) indicating respiratory 
dysfunction; this data was not available for six patients. Six patients were receiving non-invasive 
ventilation and three patients had a radiologically inserted gastrostomy. Dementia was not noted in 
the clinical files of any patient.  
 




Participants and, where appropriate patient carers were provided with a detailed explanation of the 
research aims and requirements, and informed consent was obtained; recruitment and testing 
procedures adhered to the tenets of the Declaration of Helsinki. This study was approved by the 
South East Scotland Research Ethics Committee and the University of Edinburgh’s Department of 
Psychology Ethics Committee.  
 
Procedure  
All patients and controls underwent both extensive neuropsychological assessment and, at a 
separate appointment completed within 12 weeks of assessment, the ECAS (time between 
appointments in days: mean 26.08, SD 22.25); all participants were assessed either in their own 
home or in a purpose-made clinic-based appointment. Order of completion of tests during 
neuropsychological assessment sessions followed a schedule counterbalanced across participants 
and testing was divided across multiple sessions per patient, where required, in order to minimise 
effects of fatigue. The ECAS screening data of a subset of these patients has been published 




ECAS:  The ECAS (3) is a brief 15-20 minute screen that includes assessment of the following 
domains; Fluency (Free and Fixed); Executive Functions (Reverse Digit Span, Alternation, Inhibitory 
Sentence Completion, Social Cognition); Language (Naming, Comprehension, Spelling); Memory 
(Immediate Recall, Delayed Percentage Retention, Delayed Recognition); Visuospatial Functions (Dot 
Counting, Cube Counting, Number Location). The ECAS has been carefully designed to include tasks 
that have been shown to be particularly sensitive to changes in ALS. The measures of these domains 
(fluency; executive functions and social cognition; language) combine to produce an ALS-Specific 




score, and those domains that are not normally affected in ALS (memory; visuospatial functions) are 
combined to produce an ALS Non-specific score. An ECAS total score (performance across all tasks) is 
also calculated. Previously published normative data (3) classified abnormality of performance on 
each of these sub-scores that were < 2SD below the healthy control mean: scores of less than or 
equal to 77 for ALS-Specific scores (max 100), 24 for ALS Non-specific scores (max 36) and 105 for 
ECAS total scores (max 136).  
Full Neuropsychological Assessment: Within an extensive battery of tests, five cognitive domains 
(fluency, executive function, language, memory and visuospatial function) were addressed, each via 
multiple tests (Table 1).  In addition, premorbid IQ was measured using the Test of Premorbid 
Functioning (TOPF) (21) with those participants who were able to provide verbal responses (n = 30). 
Individual physical difficulties and abilities within ALS presentation meant that certain tests were not 
completed by all patients (Test of Premorbid Functioning; Name Recognition - The Doors and People 
Test; Written Verbal Fluency; Spoken Verbal fluency), while others were adapted where required 
such that, verbal, written or pointing responses were accepted. For tests of spelling (Graded 
Difficulty Spelling Test; Psycholinguistic Assessment of Language Processing in Aphasia) participants 
who spoke their answers were given the option of seeing their responses written down and 
participants who wrote their answers were given the option of having their letters read aloud to 
them before stating their answer as final. Moreover, scoring of performance for certain tests 
deviated from standard practice (as detailed in Table 1) to accommodate use in a patient population 
with motor difficulties, for example timing in the Hayling Sentence Completion Test performance 
was implemented as a latency measurement of the difference between the two component 
conditions rather than as a measurement of only the second of these components. In addition 
affective screening was undertaken using the Hospital Anxiety and Depression Scale (HADS) (22). 




The data from healthy controls were used to create standardized Z scores for each measure. Patients 
were judged to be impaired overall if they showed a deficit on any of the targeted five domains; 
determination of a deficit in a domain is detailed below.  
 Composite scores were produced for some cognitive domains and subdomains. For each composite 
score performance < 2SD classified impairment. Where subdomains were present (for example, 
executive functions) impairment was classified where deficit was exhibited in 2 out of 3 subdomains; 
where multiple tests were used to index a subdomain (for example, shifting), or directly a domain 
(for example, memory), performance <2 SD in 1 of 2, or 2 of 3 task performances, or a single 
composite was used to determine impairment (see Table 1).  
Statistical Analyses  
Demographic and cognitive data were characterised and compared using SPSS V.20. Between-group 
comparisons were made via t-tests, and Pearson’s and Spearman’s correlations were used to detail 
relationships between measures. Receiver operating characteristics (ROC) curve analyses and area 
under the curve (AUC) was used to evaluate the ability of the ECAS screen to detect cognitive change 
in an ALS population (statistics carried out in MedCalc V. 14.10.2).  
 
  






Patient and healthy control groups displayed no significant differences in age, years of education, full 
scale (premorbid) IQ as measured through the TOPF (21), or gender distribution. While the two 
groups were comparable on mean anxiety scores, as measured through the HADS (22), patients as a 
group reported higher depression scores in the HADS than did controls (see Table 2). Further 
investigation of demographic details through correlations in the patient group demonstrated no 
relation between ECAS Total scores and ALSFRS or SNIP or Anxiety measures, however a negative 
correlation with age (r = - 0.44, p<0.01) and a positive correlation with education (rho = 0.41, p< 
0.01) emerged.  
 
Neuropsychological Assessment  
Analyses of the neuropsychological assessment revealed that 13 of the 40 ALS patients were 
classified as impaired in domains known to be affected in ALS (fluency, executive, language, or any 
combination of these domains), giving a prevalence of 33% (95% CI 18-48). Of the pattern of ALS 
impairment in these patients, 9 showed single domain impairment (1 fluency, 4 executive, 4 
language) while 4 showed a mixed profile. Of those with a multidomain profile 2 showed two 
domain impairment (1 displayed both fluency and executive deficits and 1 displayed both executive 
and language deficits) and 2 showed deficits in the fluency, executive, and the language domain. 
Three of the above 13 patients were also impaired in the memory or the visuospatial domain; a 
further one patient showed impairment solely in the visuospatial domain (see Table 3).  
ECAS ALS-Specific impairment: 




The main aim of the analysis was to assess the ability of the ECAS to identify ALS specific impairment 
in an ALS population. Two main scores are used for this purpose in the ECAS: the ALS-Specific score 
and the ECAS-Total score. Of the 13 patients who were categorized with ALS specific forms of 
impairment at neuropsychological testing, 11 were identified using the ECAS ALS-Specific score or 
the ECAS-Total score measures. The two patients who were not identified by the ECAS as impaired 
showed sole language or executive deficits only (see Table 3, patients 19 and 11 respectively). 
Overall, combined use of ECAS ALS-Specific scores and total scores revealed 85% sensitivity and 85% 
specificity (PPV 0.73, NPV 0.92) in the detection of cognitive impairment characteristic of ALS 
(fluency, executive function, language). Separately the ECAS’s ALS-Specific score displayed 77% 
sensitivity and 89% specificity (PPV 0.77, NPV 0.89), and the ECAS-Total score displayed 69% 
sensitivity and 89% specificity (PPV 0.75, NPV 0.86) to ALS specific impairment.  
ROC curves allow further consideration of the ECAS ALS-Specific and Total measures by, rather than 
considering only the sensitivity and specificity of pre-defined cut-off scores, plotting the trade-off 
that would occur between sensitivity (true positive rate) and 1-specificity (false positive rate) at each 
possible cut-off score on these measures (see Figure 1).  This analysis also indicated that sensitivity 
could be increased (by raising cut-off scores) without much compromise on specificity (see Table 4). 
Analysis of the area under the ROC curve provides a single value to represent the discriminatory 
capacity of the measures: the closer the AUC value is to 1 (perfect discrimination capacity) and 
hence the further the AUC is from 0.5 (chance performance), the better the measure is in accurately 
classifying patients. The ALS-Specific score produced an AUC of 0.93 (95% CI 0.80 to 0.99), while 
separately ROC analysis of the ECAS-total score produced an AUC of 0.91 (95% CI 0.77 to 0.98), 
indicating both measures have a high sensitivity over a range of specificities.  
ECAS ALS Non-specific impairment: 




The two patients demonstrating memory impairment at neuropsychological testing were identified 
via the ECAS ALS-Nonspecific score (see Table 3). Of the 2 patients who presented with a visuospatial 
deficit, one was identified at screening via the ECAS-Total score, but not the ALS Non-specific score.  
ECAS –Cognitive Domains 
The ability of the ECAS screen to indicate impairment in each of the five domains using published 
cut-off scores (3) and when compared against the neuropsychological assessment is detailed in Table 
5.  Analyses were also undertaken to determine which individual subtests had the greatest 
sensitivity and specificity to detect the presence of an ALS-Specific impairment at neuropsychological 
testing. The highest sensitivity of individual tests within the ECAS was for Alternation (54% sensitivity 
and 85% specificity) Spelling (44% sensitivity and 78% specificity), Fixed Fluency (46% sensitivity and 
88% specificity) and Social Cognition (38% sensitivity and 100% specificity) for overall impairment. 
The Executive domain score on its own had 57% sensitivity and 85% specificity, the language domain 
had 85% sensitivity and 74 % specificity, and fluency 46% and 75% to detect overall impairment. The 
findings suggest that the each domain has high sensitivity and specificity against neuropsychological 
assessment, but should be used as a whole test to increase sensitivity and specificity overall. 
  





The findings of this study demonstrate that the ECAS is an effective method for detecting the range 
of cognitive impairment present in ALS.  The patients sampled here showed a typical profile of 
cognitive impairment on extensive neuropsychological assessment with 33% of the patients 
displaying a combination of deficits in fluency, language and executive functions. This frequency is 
similar to that found in other larger studies (23, 24). The most typical impairment (23% of all 
patients) was in a single cognitive domain with either executive or language dysfunction, the latter is 
consistent with recent reports demonstrating the prevalence of language dysfunction in ALS (25, 26, 
27, 28). The independence of these deficits highlights the need for comprehensive screening 
covering both domains. 
The ECAS demonstrated high sensitivity and specificity in detecting overall impairment (85% 
sensitivity and 85% specificity) and an inspection of the ROC analyses indicated that a borderline 
range of Total Scores 105-110 and ALS-Specific scores 77-82 may optimize usage. However the 
significant correlations with age and education should also be taken into consideration, for example 
a borderline score may be considered as a possible impairment in a younger well educated individual 
in comparison with an older less educated person. Future normative data should accommodate for 
these parameters. Individual domain scores also demonstrated good sensitivity and specificity 
against detailed neuropsychology and may therefore be used to detect the subtleties of the 
cognitive profile. However the findings demonstrated that the effectiveness of domain or individual 
tests at detecting overall impairment (outside of that domain) was reduced and as such it is 
suggested that the test be used as a whole with overall scores indicating cognitive impairment.  
Some patients did not meet criteria for cognitive impairment on the neuropsychological battery but 
showed an impairment on a single test/domain. The current criteria for impairment was based on 
other classification methods (29) with the aim of reducing false positives. However follow up 




investigation would be of interest to determine the relevance, persistence or progression of these 
isolated deficits. 
The ECAS elicited a false positive result in four cases on either the ECAS-Total score and/or ALS-
Specific score. In three of the four cases the scores were very close to the cut-off for abnormality 
differing by only 1 or 2 points (patient 35, ALS-Specific 78 Borderline, ECAS Total 104; patient 32, 
ALS-Specific 75, ECAS Total 104; patient 29 ALS-Specific 77, ECAS Total 106). As such these three 
cases are falling on the margins of abnormality and follow up full neuropsychological assessment 
would have demonstrated intact functions. It is of interest that one of the patients (patient 29) is 
impaired on Inhibition, but given the strict criteria employed here for measuring impairment they do 
not classify as impaired. Similarly the remaining patient (patient 26) has more evidence of 
impairment on the ECAS (ALS-Specific 67, ECAS Total 97), but they are impaired only on the Test of 
Reception of Grammar at neuropsychological assessment.  Long term follow up of these patients 
may be of interest to determine whether there is further progression of these impairments. 
In conclusion, validation against gold standard extensive neuropsychology demonstrated that the 
ECAS is a screening tool with high sensitivity and specificity to impairment characteristic of ALS. The 
ECAS is an effective within clinic assessment for ALS that determines the presence, severity and type 
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TABLES AND FIGURES 
Table 1:  Neuropsychological Assessment 
Domain Subdomain: 
 





Written Phonemic verbal fluency index (VFI) (8); words beginning with ‘S’* and 4-
letter words beginning with ‘C’* 
Spoken Phonemic verbal fluency index (VFI) (8) ; words beginning with ‘P’*, ‘R’*, ‘W’* 
Executive  
Inhibition Hayling Sentence Completion Test (9): total unconnected errors (converted 
but not scaled); latency score (time taken to complete unconnected 
sentences minus time taken to complete connected sentences)  
Shifting & rule detection Brixton Spatial Anticipation test (9): total number correct 
Card Sorting test from Delis-Kaplan Executive Function System (10): sorting 
score (scaled for age) 
Social Reading the mind in the Eyes – revised version (11):  total number correct 
Judgment of Preference (12): total score  (graded scoring, recognising correct 
answers, random responses and egocentric responses separately)   
Language  
Naming Boston naming test (13): total number correct * 
Graded Naming test (14): total number correct* 
Spelling Graded Difficulty Spelling Test (15): (Form A) total number correct* 
Psycholinguistic Assessment of Language Processing in Aphasia (16): (subtest 
Grammatical Class Spelling: nouns and verbs) total number correct* 
Comprehension Test of Reception of Grammar version 1 (17): number of blocks passed 
Memory  BIRT Memory and Information Processing Battery (18): immediate story 
recall; delayed story recall (percent retained). 
The Doors and People Test (19): name recognition score (scaled for age) 
Visuospatial 
function 
 The Visual Object and Space Perception Battery (20): Dot Count subtest*; 
Cube Analysis*; Number Location*. 









Table 2: Demographics of Participants 
 Patients Controls t (df)/ 2(df) 
Significance 
(p<0.05) 
























































TOPF: Test of Premorbid Function, FSIQ: Full Scale IQ, HADS: Hospital Anxiety and Depression Scale. 
ns = non significant. 
  




 Table 3.  Impairment in Neuropsychological Domains and ECAS in 40 MND patients 






1  X - I S SC    X  B 
2  S    B   
3         
4 X X - I S SC  X - N T  X  X X X 
5         
6         
7 X S    X  X 
8  I       
9  I       
10  SC X - N T  X  X X X 
11  X - I SC Sp   B  B 
12  I       
13         
14         
15         
16  SC X – N T    X  X 
17         
18  X - I S SC X - N T   X B  X 
19  SC X - T Sp       
20  S   X    
21         
22  S       
23  X - I S     X  B 
24         
25   X - T Sp    X  X 
26   T   X  X 
27         
28  X - I S SC    X  X 
29  I    X  B 
30  SC       
31 X X - I S SC  T   X  X 
32      X  X 
33      B  B 
34         
35      B  X 
36         
37         
38  I       
39  S       
40 X X – I S SC X- N T S   X  X 
VSP: Visuospatial functions, nSpec: non-specific. I: Inhibition, S: Shifting, SC: Social Cognition, N: 
Naming, T: Test of Reception of Grammar, Sp: Spelling, B: Borderline. X marks overall impairment 
classification.  




Table 4: Sensitivity, specificity and predictive values of current and alternative cut-off values for ALS-
Specific and ECACS-Total measures 







score cut-off     
<77 0.77 0.89 0.77 0.89 
≤78 0.85 0.81 0.69 0.92 
≤80 0.92 0.81 0.71 0.92 
< 82 0.92 0.74 0.63 0.95 
≤83 1.00 0.74 0.65 1.00 
ECAS Total 
Score cut-off 
    
<105 0.69 0.89 0.75 0.86 
≤107 0.77 0.81 0.67 0.88 
≤108 0.85 0.81 0.69 0.92 
≤110 0.92 0.81 0.71 0.96 
≤115 1.00 0.52 0.50 1.00 
Note: current cut-off values in bold; cut-offs with duplicated sensitivity values are omitted 
  





Table 5: Sensitivity, specificity and predictive values of individual domain cut-off scores to detect 
analogous domain impairment at neuropsychological assessment 








1.00 0.83 0.40 1.00 
Executive 
(33/48) 
0.63 0.78 0.42 0.89 
Language 
(26/28) 
0.86 0.64 0.33 0.95 
Memory 
(13/24) 
1.00 1.00 1.00 1.00 
Visuospatial 
(10/12) 
0.50 1.00 1.00 0.97 
Figures in parentheses are previously published cut-off scores and maximum scores per domain (3) 
 
  





Figure 1: ROC curve for ECAS ALS-Specific (Panel A) and ECAS total scores (Panel B) as detecting ALS 
Specific cognitive impairment.  
 
 
